CYP3A-status is associated with blood concentration and dose-requirement of tacrolimus in heart transplant recipients

CYP3A-status is associated with blood concentration and dose-requirement of tacrolimus in heart transplant recipients

Abstract High inter-individual variability in tacrolimus clearance is attributed to genetic polymorphisms of CYP3A enzymes. However, due to CYP3A phenoconversion induced by non-genetic factors, continuous changes in tacrolimus-metabolizing capacity entail frequent dose-refinement for optimal immunos...

Full description

Bibliographic Details
Main Authors:	Máté Déri, Zsófia Szakál-Tóth, Ferenc Fekete, Katalin Mangó, Evelyn Incze, Annamária Minus, Béla Merkely, Balázs Sax, Katalin Monostory
Format:	Article
Language:	English
Published:	Nature Portfolio 2021-11-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-021-00942-y

Similar Items

CYP1A2 mRNA Expression Rather than Genetic Variants Indicate Hepatic CYP1A2 Activity
by: Ferenc Fekete, et al.
Published: (2022-02-01)

CYP1A2 expression rather than genotype is associated with olanzapine concentration in psychiatric patients
by: Ferenc Fekete, et al.
Published: (2023-10-01)

Potential Association of Cytochrome P450 Copy Number Alteration in Tumour with Chemotherapy Resistance in Lung Adenocarcinoma Patients
by: Evelyn Incze, et al.
Published: (2023-08-01)

Association between CYP2B6 genetic variability and cyclophosphamide therapy in pediatric patients with neuroblastoma
by: Katalin Mangó, et al.
Published: (2023-07-01)

Seroconversion after SARS‐CoV‐2 vaccination is protective against severe COVID‐19 disease in heart transplant recipients
by: Szilvia Kugler, et al.
Published: (2023-11-01)

Acute heart transplantation from mechanical circulatory support in a human immunodeficiency virus‐positive patient with fulminant myocarditis
by: Zsofia Szakal‐Toth, et al.
Published: (2021-04-01)

Pseudoaneurysm of the ascending aorta: case report of a donor-derived Pseudomonas infection in a heart transplant recipient
by: Szilvia Kugler, et al.
Published: (2021-08-01)

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment
by: Chen L, et al.
Published: (2018-03-01)

The impact of CYP3A5 and MDR1 polymorphisms on tacrolimus dosage requirements and trough concentrations in pediatric renal transplant recipients
by: Sireen Shilbayeh, et al.
Published: (2013-01-01)

Investigation of clinical interaction between omeprazole and tacrolimus in CYP3A5 non-expressors, renal transplant recipients
by: Paraskevi F Katsakiori, et al.
Published: (2010-06-01)

Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients.
by: Chuan-Jiang Li, et al.
Published: (2014-01-01)

Impact of Tacrolimus Daily Dose Limitation in Renal Transplant Recipients Expressing CYP3A5: A Retrospective Study
by: Rémi Lenain, et al.
Published: (2021-10-01)

Personalized tacrolimus dose requirement by CYP3A5 but not ABCB1 or ACE genotyping in both recipient and donor after pediatric liver transplantation.
by: Yi-kuan Chen, et al.
Published: (2014-01-01)

Single Nucleotide Polymorphisms of CYP3A4 and CYP3A5 in Romanian Kidney Transplant Recipients: Effect on Tacrolimus Pharmacokinetics in a Single-Center Experience
by: Corina Andreea Rotarescu, et al.
Published: (2024-03-01)

Impact of CYP3A7, CYP2D6 and ABCC2/ABCC3 polymorphisms on tacrolimus steady state concentrations in Bulgarian kidney transplant recipients
by: Tsvetelin Lukanov, et al.
Published: (2022-12-01)

The Clinical Impact of the C0/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients
by: Teun van Gelder, et al.
Published: (2020-07-01)

Tacrolimus monitoring in hair samples of kidney transplant recipients
by: Alexander Born, et al.
Published: (2023-12-01)

Effect of cyclosporin and tacrolimus on kidney function in liver recipients
by: Elena D. Kosmacheva, et al.
Published: (2018-09-01)

Donor <i>CYP3A5</i> Gene Polymorphism Alone Cannot Predict Tacrolimus Intrarenal Concentration in Renal Transplant Recipients
by: Mengyu Zhang, et al.
Published: (2020-04-01)

Melding Pharmacogenomic Effect of MDR1 and CYP3A5 Gene Polymorphism on Tacrolimus Dosing in Renal Transplant Recipients in Northern India
by: Narayan Prasad, et al.
Published: (2020-01-01)

Effects of the CYP3A4*1B Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Adult Renal Transplant Recipients: A Meta-Analysis.
by: Wei-Long Shi, et al.
Published: (2015-01-01)

Commentary: The Clinical Impact of the C0/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients
by: Gerold Thölking, et al.
Published: (2021-02-01)

Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients
by: Michele Pinon, et al.
Published: (2021-01-01)

BGP-15 Protects against Oxidative Stress- or Lipopolysaccharide-Induced Mitochondrial Destabilization and Reduces Mitochondrial Production of Reactive Oxygen Species.
by: Katalin Sumegi, et al.
Published: (2017-01-01)

Automated T1 and T2 mapping segmentation on cardiovascular magnetic resonance imaging using deep learning
by: András Kalapos, et al.
Published: (2023-07-01)

Evaluating the Impact of CYP3A5 Genotype on Post-Transplant Healthcare Resource Utilization in Pediatric Renal and Heart Transplant Recipients Receiving Tacrolimus
by: Pasternak AL, et al.
Published: (2021-03-01)

In Vitro Pharmacokinetic Behavior of Antiviral 3-Amidinophenylalanine Derivatives in Rat, Dog and Monkey Hepatocytes
by: Katalin Lányi, et al.
Published: (2023-02-01)

Limited sampling strategies for estimation of tacrolimus exposure in kidney transplant recipients receiving extended‐release tacrolimus preparation
by: Toqa El‐Nahhas, et al.
Published: (2022-01-01)

Pharmacokinetics of apixaban and tacrolimus or cyclosporine in kidney and lung transplant recipients
by: Holly Mansell, et al.
Published: (2022-07-01)

Pharmacokinetics of tacrolimus according to body composition in recipients of kidney transplants
by: Seung Seok Han, et al.
Published: (2012-09-01)

Estimation of Tacrolimus Clearance in Saudi Adult Kidney Transplant Recipients
by: Saeed Alqahtani, et al.
Published: (2021-01-01)

Recipient Pericardial Apolipoprotein Levels Might Be an Indicator of Worse Outcomes after Orthotopic Heart Transplantation
by: Andrea Székely, et al.
Published: (2024-02-01)

Effects of CYP3A4*22 and POR*28 variations on the pharmacokinetics of tacrolimus in renal transplant recipients: a meta-analysis of 18 observational studies
by: Ze Li, et al.
Published: (2024-02-01)

Relationship between CYP3A5 Polymorphism and Tacrolimus Blood Concentration Changes in Allogeneic Hematopoietic Stem Cell Transplant Recipients during Continuous Infusion
by: Naoki Yoshikawa, et al.
Published: (2021-04-01)

Genetic, clinical and imaging implications of a noncompaction phenotype population with preserved ejection fraction
by: Kinga Grebur, et al.
Published: (2024-02-01)

Properties of Cellulose Sheets Modified with Potassium-Humate and Copper (II)-Sulfate
by: Annamária Tóth, et al.
Published: (2019-03-01)

Influence of Venoarterial Extracorporeal Membrane Oxygenation Integrated Hemoadsorption on the Early Reversal of Multiorgan and Microcirculatory Dysfunction and Outcome of Refractory Cardiogenic Shock
by: Adam Soltesz, et al.
Published: (2022-11-01)

Severe anorexia and weight loss induced by tacrolimus in kidney transplant recipients
by: Hong Pil Hwang, et al.
Published: (2021-06-01)

Drug–Drug Interaction between Tacrolimus and Vonoprazan in Kidney Transplant Recipients
by: Yoshiharu Suzuki, et al.
Published: (2021-08-01)

LCP-tacrolimus in long-term kidney graft recipients: Dosing and adherence
by: Yvonne Schill, et al.
Published: (2023-09-01)